SciELO - Scientific Electronic Library Online

 
vol.66 número2Micobacteriosis pulmonar en pacientes HIV negativos en la ciudad de Buenos Aires, años 2003-2004Paquidermoperiostosis (osteoartropatía hipertrófica primaria) índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Medicina (Buenos Aires)

versión impresa ISSN 0025-7680versión On-line ISSN 1669-9106

Resumen

DENNINGHOFF, Valeria; FALCO, Jorge; CURUTCHET, H. Pablo  y  ELSNER, Boris. Study of the sentinel lymph node: Diagnosis and treatment of cutaneous malignant melanoma stages I and II. Medicina (B. Aires) [online]. 2006, vol.66, n.2, pp.144-146. ISSN 0025-7680.

Survival at 5 years of patients with localized primary malignant melanoma is about 80%, compared with a 35% survival in case of lymph nodes involvement. Sentinel lymph node(s) from 45 subjects with diagnosis of malignant melanoma stage I or II was/were studied with hematoxylin-eosin (HE), immunohistochemistry (IHC) and molecular biology (MB) techniques. The population was divided into three groups: HE-/IHC+/MB+, where 67% patients died; HE-/IHC-/MB+, where 57% died; and HE-/IHC-/MB-, where 100% of the patients are alive, with no lymphadenectomy and a median follow-up of 60 months. Those subjects who showed negativity with all the three methods had a null recurrence rate. Data herein obtained suggest a new molecular oncological staging, which would allow the selection of patients with submicroscopic metastases for a complete treatment. Moreover, several patients with no lymph node metastases should not undergo lympha-denectomies, and overtreatment could therefore be avoided.

Palabras clave : malignant cutaneous melanona; sentinel lymph node; tyrosinase.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons